ADAM17 and acute myeloid leukemia: Nonetheless, we found that DAC significantly reduced ADAM17 activity in untreated and DAC-treated AML cells (p = 0.01 for KG1a and p = 0.039 for NB4) when analyzed by a fluorometric assay (Figure 3C).